Genetic testing firm GeneDx posted a 49% increase in Q2 revenue driven by higher volumes of whole-exome and whole-genome sequencing tests, marking its fourth consecutive profitable quarter. The company raised its full-year 2025 revenue guidance to a range of $400 million to $415 million, citing improved reimbursement and expanded market opportunities, particularly in general pediatrics. CEO Katherine Stueland highlighted the company's initiatives to educate providers and payers to support test adoption consistent with new clinical guidelines.